{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:13:45Z","timestamp":1793664825605,"version":"4.5.1"},"reference-count":56,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014653","name":"Manchester Biomedical Research Centre","doi-asserted-by":"publisher","award":["NIHR203308"],"award-info":[{"award-number":["NIHR203308"]}],"id":[{"id":"10.13039\/100014653","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.autrev.2025.103837","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T11:32:44Z","timestamp":1747999964000},"page":"103837","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Dual B-cell targeting in systemic lupus erythematosus: The role of combined and sequential therapy with rituximab and belimumab"],"prefix":"10.1016","volume":"24","author":[{"given":"Beatriz","family":"Frade-Sosa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan C.","family":"Sarmiento-Monroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian N.","family":"Bruce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Arnaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 A.","family":"G\u00f3mez-Puerta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.autrev.2025.103837_bb0005","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1001\/jama.2024.2315","article-title":"Systemic lupus erythematosus","volume":"331","author":"Siegel","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.autrev.2025.103837_bb0010","first-page":"2","article-title":"Systemic lupus erythematosus","author":"Kaul","year":"2016","journal-title":"Nat Rev Dis Primers"},{"issue":"12","key":"10.1016\/j.autrev.2025.103837_bb0015","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1136\/annrheumdis-2017-211663","article-title":"Survival in adults and children with systemic lupus erythematosus: a systematic review and Bayesian meta-analysis of studies from 1950 to 2016","volume":"76","author":"Tektonidou","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2025.103837_bb0020","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.autrev.2025.103837_bb0025","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.autrev.2025.103837_bb0030","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of Anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.autrev.2025.103837_bb0035","doi-asserted-by":"crossref","first-page":"3612","DOI":"10.1002\/art.22211","article-title":"B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles","volume":"54","author":"Cambridge","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.autrev.2025.103837_bb0040","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.1002\/art.20592","article-title":"Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus","volume":"50","author":"Anolik","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"Supplement_5","key":"10.1016\/j.autrev.2025.103837_bb0055","doi-asserted-by":"crossref","first-page":"v29","DOI":"10.1093\/rheumatology\/keaa382","article-title":"Long-term outcomes in systemic lupus erythematosus: trends over time and major contributors","volume":"59","author":"Arnaud","year":"2020","journal-title":"Rheumatology"},{"issue":"9","key":"10.1016\/j.autrev.2025.103837_bb0060","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.cgh.2018.02.024","article-title":"Combining biologics in inflammatory bowel disease and other immune mediated inflammatory disorders","volume":"16","author":"Hirten","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.autrev.2025.103837_bb0065","doi-asserted-by":"crossref","first-page":"e361","DOI":"10.1016\/j.cgh.2021.03.034","article-title":"Dual biologic or small molecule therapy for treatment of inflammatory bowel disease: a systematic review and Meta-analysis","volume":"20","author":"Ahmed","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.autrev.2025.103837_bb0070","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1002\/ueg2.12170","article-title":"Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune-mediated inflammatory diseases: a European retrospective observational study","volume":"9","author":"Goessens","year":"2021","journal-title":"United European Gastroenterol J"},{"issue":"1","key":"10.1016\/j.autrev.2025.103837_bb0075","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/jcag\/gwad032","article-title":"Current evidence for combined targeted therapy for the treatment of inflammatory bowel disease","volume":"7","author":"Wetwittayakhlang","year":"2024","journal-title":"J Can Assoc Gastroenterol"},{"issue":"2","key":"10.1016\/j.autrev.2025.103837_bb0080","doi-asserted-by":"crossref","DOI":"10.5041\/RMMJ.10494","article-title":"Dual biologic therapy in patients with rheumatoid arthritis and psoriatic arthritis","volume":"14","author":"Furer","year":"2023","journal-title":"Rambam Maimonides Med J"},{"issue":"1","key":"10.1016\/j.autrev.2025.103837_bb0085","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.semarthrit.2018.12.003","article-title":"Safety of combination therapy with two bDMARDs in patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"49","author":"Boleto","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103837_bb0090","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jaut.2018.03.003","article-title":"The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus","volume":"91","author":"Kraaij","year":"2018","journal-title":"J Autoimmun"},{"issue":"8","key":"10.1016\/j.autrev.2025.103837_bb0095","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1093\/ndt\/gfaa117","article-title":"Long-term effects of combined B-cell immunomodulation with rituximab and belimumab in severe, refractory systemic lupus erythematosus: 2-year results","volume":"36","author":"Kraaij","year":"2021","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1016\/j.autrev.2025.103837_bb0100","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2024-001424","article-title":"Long-term safety and efficacy of the combination of belimumab and rituximab in the treatment of severe and refractory SLE: a preliminary report","volume":"12","author":"van Schaik","year":"2025","journal-title":"Lupus Sci Med"},{"issue":"12","key":"10.1016\/j.autrev.2025.103837_bb0105","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-032569","article-title":"Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial","volume":"9","author":"Jones","year":"2019","journal-title":"BMJ Open"},{"issue":"11","key":"10.1016\/j.autrev.2025.103837_bb0110","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1136\/ard-2024-225686","article-title":"Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study","volume":"83","author":"Aranow","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2025.103837_bb0115","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/art.41466","article-title":"Phase II randomized trial of rituximab plus cyclophosphamide followed by Belimumab for the treatment of lupus nephritis","volume":"73","author":"Atisha-Fregoso","year":"2021","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.autrev.2025.103837_bb0120","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1186\/s13063-022-06874-w","article-title":"Efficacy of belimumab combined with rituximab in severe systemic lupus erythematosus: study protocol for the phase 3, multicenter, randomized, open-label Synbiose 2 trial","volume":"23","author":"van Schaik","year":"2022","journal-title":"Trials"},{"issue":"2","key":"10.1016\/j.autrev.2025.103837_bb0125","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/1756-185X.12463","article-title":"Current role of rituximab in systemic lupus erythematosus","volume":"18","author":"Mok","year":"2015","journal-title":"Int J Rheum Dis"},{"issue":"6","key":"10.1016\/j.autrev.2025.103837_bb0130","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1111\/ajt.12220","article-title":"A single dose of rituximab does not deplete B cells in secondary lymphoid organs but alters phenotype and function","volume":"13","author":"Kamburova","year":"2013","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1016\/j.autrev.2025.103837_bb0135","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s40265-018-0872-z","article-title":"Belimumab: a review in systemic lupus erythematosus","volume":"78","author":"Blair","year":"2018","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.autrev.2025.103837_bb0140","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nrrheum.2016.18","article-title":"The BAFFling effects of rituximab in lupus: danger ahead?","volume":"12","author":"Ehrenstein","year":"2016","journal-title":"Nat Rev Rheumatol"},{"issue":"7","key":"10.1016\/j.autrev.2025.103837_bb0145","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1002\/art.34400","article-title":"Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus","volume":"64","author":"Stohl","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.autrev.2025.103837_bb0150","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1002\/art.39710","article-title":"Checkpoints for autoreactive B cells in the peripheral blood of lupus patients assessed by flow cytometry","volume":"68","author":"Malkiel","year":"2016","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.autrev.2025.103837_bb0155","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/S2665-9913(22)00332-0","article-title":"Identification of biomarkers to stratify response to B-cell-targeted therapies in systemic lupus erythematosus: an exploratory analysis of a randomised controlled trial","volume":"5","author":"Shipa","year":"2023","journal-title":"Lancet Rheumatol"},{"issue":"12","key":"10.1016\/j.autrev.2025.103837_bb0160","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1038\/ajg.2015.355","article-title":"Vedolizumab and infliximab combination therapy in the treatment of Crohn\u2019s disease","volume":"110","author":"Hirten","year":"2015","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.autrev.2025.103837_bb0165","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/ibd.20014","article-title":"Safety and tolerability of concurrent natalizumab treatment for patients with Crohn\u02bcs disease not in remission while receiving infliximab","volume":"13","author":"Sands","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.autrev.2025.103837_bb0170","first-page":"14","article-title":"Dual targeted therapy in patients with psoriatic arthritis and spondyloarthritis: a real-world multicenter experience from Spain","author":"Valero-Mart\u00ednez","year":"2023","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2025.103837_bb0175","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1365-2230.2007.02673.x","article-title":"When there is no single best biological agent: psoriasis and psoriatic arthritis in the same patient responding to two different biological agents","volume":"33","author":"Adi\u015fen","year":"2008","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"10.1016\/j.autrev.2025.103837_bb0180","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1111\/bjd.14270","article-title":"Combination of antitumour necrosis factor-\u03b1 and anti-interleukin-12\/23 antibodies in refractory psoriasis and psoriatic arthritis: a long-term case-series observational study","volume":"174","author":"Gniadecki","year":"2016","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.autrev.2025.103837_bb0185","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jdcr.2014.09.002","article-title":"Combined biologic therapy for the treatment of psoriasis and psoriatic arthritis: a case report","volume":"1","author":"Babalola","year":"2015","journal-title":"JAAD Case Rep"},{"issue":"1","key":"10.1016\/j.autrev.2025.103837_bb0190","doi-asserted-by":"crossref","first-page":"187.2","DOI":"10.3899\/jrheum.110295","article-title":"Combination biologic treatment of refractory psoriasis and psoriatic arthritis","volume":"39","author":"Cuchacovich","year":"2012","journal-title":"J Rheumatol"},{"issue":"10","key":"10.1016\/j.autrev.2025.103837_bb0195","first-page":"1098","article-title":"Combination use of ustekinumab with other systemic therapies: a retrospective study in a tertiary referral center","volume":"12","author":"Heinecke","year":"2013","journal-title":"J Drugs Dermatol"},{"issue":"9","key":"10.1016\/j.autrev.2025.103837_bb0200","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1002\/art.22070","article-title":"Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study","volume":"54","author":"Weinblatt","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.autrev.2025.103837_bb0205","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1002\/art.39262","article-title":"Safety and efficacy of Atacicept in combination with rituximab for reducing the signs and symptoms of rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled pilot trial","volume":"67","author":"van Vollenhoven","year":"2015","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.autrev.2025.103837_bb0210","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/art.30194","article-title":"Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial","volume":"63","author":"Greenwald","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.autrev.2025.103837_bb0215","doi-asserted-by":"crossref","first-page":"599","DOI":"10.3899\/jrheum.120924","article-title":"Safety of rituximab in combination with other biologic disease-modifying Antirheumatic drugs in rheumatoid arthritis: an open-label study","volume":"40","author":"Rigby","year":"2013","journal-title":"J Rheumatol"},{"issue":"4","key":"10.1016\/j.autrev.2025.103837_bb0220","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/rheumatology\/ken491","article-title":"Safety of combination therapy with rituximab and etanercept for patients with rheumatoid arthritis","volume":"48","author":"Blank","year":"2009","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.autrev.2025.103837_bb0225","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2174\/1874312900903010009","article-title":"Sustained remission after combination therapy with rituximab and Etanercept in two patients with rheumatoid arthritis after TNF failure: case report","volume":"3","author":"Tony","year":"2009","journal-title":"Open Rheumatol J"},{"issue":"9","key":"10.1016\/j.autrev.2025.103837_bb0230","doi-asserted-by":"crossref","first-page":"2125.2","DOI":"10.3899\/jrheum.090160","article-title":"Severe refractory rheumatoid arthritis successfully treated with combination rituximab and anti-tumor necrosis factor-\u03b1-blocking agents","volume":"36","author":"Koumakis","year":"2009","journal-title":"J Rheumatol"},{"issue":"5","key":"10.1016\/j.autrev.2025.103837_bb0235","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1002\/art.20221","article-title":"Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate","volume":"50","author":"Genovese","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.autrev.2025.103837_bb0240","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1136\/ard.2006.055111","article-title":"Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial","volume":"66","author":"Weinblatt","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103837_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2025.152660","article-title":"Combotherapies in immune-mediated inflammatory diseases: a study using the clinical data warehouse from Paris hospitals\u2019 public assistance","volume":"71","author":"G\u00e9rard","year":"2025","journal-title":"Semin Arthritis Rheum"},{"issue":"23","key":"10.1016\/j.autrev.2025.103837_bb0250","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.163030","article-title":"A randomized, phase II study of sequential belimumab and rituximab in primary Sj\u00f6gren\u2019s syndrome","volume":"7","author":"Mariette","year":"2022","journal-title":"JCI Insight"},{"issue":"Supplement_1","key":"10.1016\/j.autrev.2025.103837_bb0255","doi-asserted-by":"crossref","first-page":"i22","DOI":"10.1093\/rheumatology\/keac678","article-title":"Dilemma of immunosuppression and infection risk in systemic lupus erythematosus","volume":"62","author":"He","year":"2023","journal-title":"Rheumatology"},{"issue":"6","key":"10.1016\/j.autrev.2025.103837_bb0260","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1136\/ard-2022-223335","article-title":"2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases","volume":"82","author":"Fragoulis","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2025.103837_bb0265","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","article-title":"2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases","volume":"79","author":"Furer","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.autrev.2025.103837_bb0270","doi-asserted-by":"crossref","first-page":"e331","DOI":"10.1016\/S2665-9913(24)00115-2","article-title":"Protecting patients with SLE against herpes zoster: time for early proactive vaccine counselling","volume":"6","author":"Boekel","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.autrev.2025.103837_bb0275","series-title":"Abstracts","first-page":"A16","article-title":"27\u00a0Bi-specific antibodies","author":"Furie","year":"2024"},{"issue":"1","key":"10.1016\/j.autrev.2025.103837_bb0280","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","article-title":"B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial","volume":"81","author":"Furie","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"15","key":"10.1016\/j.autrev.2025.103837_bb0285","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJMoa2410965","article-title":"Efficacy and safety of Obinutuzumab in active lupus nephritis","volume":"392","author":"Furie","year":"2025","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.autrev.2025.103837_bb0290","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1177\/09612033241237560","article-title":"Satisfaction and effectiveness of switching from intravenous to subcutaneous belimumab treatment in daily clinical practice","volume":"33","author":"Frade-Sosa","year":"2024","journal-title":"Lupus"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997225000977?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997225000977?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T19:21:23Z","timestamp":1753212083000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997225000977"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":56,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1568997225000977"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2025.103837","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual B-cell targeting in systemic lupus erythematosus: The role of combined and sequential therapy with rituximab and belimumab","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2025.103837","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103837"}}